Scarica l'app Stockscreener
52.86
0.15%
0.08
Dopo l'orario di chiusura:
52.86
Precedente Chiudi:
$52.78
Aprire:
$52.73
Volume 24 ore:
698.81K
Relative Volume:
0.34
Capitalizzazione di mercato:
$5.55B
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+0.49%
1M Prestazione:
+58.98%
6M Prestazione:
+201.20%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$52.57
$52.94
Intervallo di 1 settimana:
$52.09
$53.23
Portata 52W:
$12.30
$54.47
Metsera Inc Stock (MTSR) Company Profile
Nome
Metsera Inc
Settore
Industria
Telefono
(212) 784-6595
Indirizzo
3 WORLD TRADE CENTER, NEW YORK
Confronta MTSR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MTSR
Metsera Inc
|
52.86 | 5.53B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Metsera Inc Stock (MTSR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-30 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-09-09 | Iniziato | Leerink Partners | Outperform |
| 2025-06-20 | Iniziato | Wells Fargo | Overweight |
| 2025-02-25 | Iniziato | BofA Securities | Buy |
| 2025-02-25 | Iniziato | Evercore ISI | Outperform |
| 2025-02-25 | Iniziato | Guggenheim | Buy |
Mostra tutto
Metsera Inc Borsa (MTSR) Ultime notizie
How to manage a losing position in Metsera Inc.Market Sentiment Report & Community Trade Idea Sharing Platform - newser.com
Is Metsera Inc. stock near bottom after declineWall Street Watch & Risk Managed Trade Strategies - newser.com
A Once-in-a-Decade Investment Opportunity: 1 Pharmaceutical Stock to Buy Now Hand Over Fist and Hold for Years - The Motley Fool
Real time alert setup for Metsera Inc. performance2025 Earnings Surprises & Low Risk Entry Point Guides - newser.com
What Fibonacci levels say about Metsera Inc. reboundJuly 2025 Catalysts & Daily Risk Controlled Trade Plans - newser.com
What machine learning models say about Metsera Inc.Market Volume Summary & Fast Exit/Entry Strategy Plans - newser.com
How Metsera Inc. stock reacts to Fed rate cutsWeekly Stock Summary & Consistent Growth Equity Picks - newser.com
IP Group: Metsera deal highlights hidden value, say analysts - Proactive financial news
IP Group shares fly on back of Metsera & Pfizer news - BusinessCloud
IP Group shares climb 9% on potential royalties from Pfizer’s $7.3bn Metsera deal - Proactive financial news
IP Group notes potential income from Metsera obesity drugs - MarketScreener
IP Group Poised for Potential Royalty Windfall from Metsera’s Obesity Drug Pipeline - AskTraders.com
IP Group eyes potential royalties from obesity drug - The Armchair Trader
IP Group eyes future royalties from obesity drug candidates following Pfizer/Metsera deal - Proactive financial news
IP Group’s Edge in Obesity Drugs: Pfizer-Metsera Deal Insight - Kalkine Media
IP Group Sees Revenue Potential From Metsera Obesity Drug Deal - DirectorsTalk Interviews
IP Group Anticipates Revenue Boost from Metsera’s Obesity Drug Development - TipRanks
REGIP Group PLCPotential income from Metsera obesity drugs - TradingView
Metsera (MTSR): Evaluating Valuation After a 48% One-Month Share Price Surge - Yahoo Finance
Metsera (NASDAQ:MTSR) Receives Sell (D) Rating from Weiss Ratings - MarketBeat
Metsera Inc. stock trend forecastJuly 2025 Action & Smart Allocation Stock Tips - newser.com
How to integrate Metsera Inc. into portfolio analysis toolsQuarterly Profit Summary & AI Enhanced Trading Signals - newser.com
Pfizer Aims To Close Gap On Obesity Drugs With Metsera 09/23/2025 - MediaPost
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates UNP, MTSR, SCS on Behalf of Shareholders - The Malaysian Reserve
Novo Nordisk’s liver deal misses bigger ailment - Reuters
What data driven models say about Metsera Inc.’s futureJuly 2025 Weekly Recap & Trade Opportunity Analysis - newser.com
Does Metsera Inc. show high probability of reboundSwing Trade & Accurate Intraday Trading Signals - newser.com
Will Metsera Inc. rebound enough to break even2025 Market Sentiment & Consistent Income Trade Ideas - newser.com
Applying Elliott Wave Theory to Metsera Inc.Weekly Stock Analysis & Technical Pattern Based Signals - newser.com
Pfizer: Mastering The Art Of The Deal With MetseraUpgraded To Buy (NYSE:PFE) - Seeking Alpha
Pfizer to Buy Metsera for $4.9 Billion in Obesity Drug Bet - MSN
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Inside INdiana Business - FinancialContent
Metsera, Inc. (MTSR) Stock Analysis: Biotechnology Innovator with a 5.71% Upside Potential - DirectorsTalk Interviews
Is this a good reentry point in Metsera Inc.Exit Point & Consistent Return Investment Signals - newser.com
Is Metsera Inc. stock poised for growthWeekly Profit Analysis & Growth Focused Investment Plans - newser.com
Will earnings trigger a reversal in Metsera Inc.July 2025 PostEarnings & Verified Trade Idea Suggestions - newser.com
Is Metsera Inc. stock resilient to inflationJuly 2025 Highlights & Daily Stock Trend Watchlist - newser.com
Market Movers: Metsera and Apple surge, Kenvue falters on Tylenol troubles - MSN
Where Metsera’s data fit in the obesity landscape - biocentury.com
Will Metsera Inc. stock split again soonWeekly Market Report & Expert Curated Trade Setup Alerts - newser.com
Metsera (NASDAQ:MTSR) Raised to "Hold" at Wall Street Zen - MarketBeat
Metsera Inc Azioni (MTSR) Dati Finanziari
Non sono disponibili dati finanziari per Metsera Inc (MTSR). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
Metsera Inc Azioni (MTSR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Burow Kristina | Director |
Feb 03 '25 |
Buy |
18.00 |
2,222,222 |
39,999,996 |
18,503,128 |
| BERNS PAUL L | Director |
Feb 03 '25 |
Buy |
18.00 |
789,998 |
14,219,964 |
8,313,680 |
| ARCH Venture Partners XII, LLC | 10% Owner |
Feb 03 '25 |
Buy |
18.00 |
2,222,222 |
39,999,996 |
18,503,128 |
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):